Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on April 20, 2015, covering events that occurred on April 16, 2015. The filing addresses changes to the Board of Directors and executive compensation arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- Board Appointment: Jeff Baxter was appointed to the Board of Directors. Mr. Baxter brings 19 years of pharmaceutical experience, including roles at GlaxoSmithKline (GSK) and VBI Vaccines Inc., with expertise in R&D finance, operations, and venture capital.
- Board Resignation: Mark Germain resigned from the Board. The resignation was not due to any disagreement with the Company's operations, policies, or practices.
- Compensation Adjustment: The Board approved an increase in the base salary of Chief Operating Officer Troy Rhonemus from $190,000 to $215,000. This increase is contingent upon the Company listing its common stock on a national securities exchange.
- Resignation Compensation: The Board granted Mr. Germain 125,000 shares of restricted stock as compensation for his services, which vest immediately.
Guidance, Outlook, and Risks
The filing notes a specific risk regarding the executive compensation adjustment: there is no guarantee that the Company will successfully list its common stock on a national securities exchange or comply with the rules of such an exchange. No financial guidance or outlook was provided in this report.
Key Facts for Investor Verification
- Verify the Company's current status regarding listing on a national securities exchange to determine if the COO's salary increase is effective.
- Confirm the immediate vesting and valuation of the 125,000 restricted shares granted to the departing director, Mark Germain.
- Review the Company's subsequent filings to assess the impact of Jeff Baxter's appointment on strategic direction and R&D planning.